AR and prostate carcinoma: In the subsequent studies, they found another compound ARD-266, with an effective AR antagonist and a VHL ligand (weak binding affinity to VHL), also effectively induced AR protein degradation with a low DC50 value (0.2–1 nM) in prostate cancer cells [30].